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ABSTRACT
Numerous studies demonstrated an importance of cytochrome P-450 epoxygenase pathway of arachi-
donic acids metabolism for the pathogenesis of essential hypertension (EH). The present study was
designed to investigate whether common single-nucleotide polymorphisms (SNP) of CYP2C gene
subfamily such as CYP2C8 (rs7909236 and rs1934953), CYP2C9 (rs9332242), and CYP2C19 (rs4244285)
are associated with susceptibility to EH in Russian population. A total of 816 unrelated Russian
individuals comprising 425 EH patients and 391 normotensive controls were included into the study.
Genotyping of SNPs was performed using the MassARRAY 4 system. SNP rs7909236 of CYP2C8 was
significantly associated with increased risk of EH (OR adjusted for sex and age was 2.99 95% CI 1.39-6.44,
P = 0.005). SNPs rs1934953 CYP2C8 and rs4244285 of CYP2C19 showed association with EH risk but at a
borderline statistical significance (P ≤ 0.04). Combination of genotypes CYP2C8 rs7909236 TT and
CYP2C19 rs4244285 GG was associated with increased EH risk (OR 3.34 95%CI 1.48-7.51, P = 0.004).
Genotype–phenotype correlation analysis showed that the levels of CYP2C8 mRNA were significantly
correlated with SNP rs7909236 (P = 0.01). in silico functional prediction analysis revealed the function-
ality of majority of investigated SNPs. Thus, genes of CYP2C subfamily are important genetic determi-
nants of susceptibility to essential hypertension in Russians.
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Introduction
Hypertension is a complex multifactorial disease with high world-
wide prevalence and associated increased rates of morbidity,
mortality, and disability from cardiovascular and cerebrovascular
diseases (1, 2). Despite considerable research, the etiology of
hypertension in most cases remains elusive, that is, the reason to
define the disease as essential hypertension (EH). Although, gen-
ome-wide association scans and candidate gene studies have
successfully identified a number of common genetic variants
influencing blood pressure and hypertension susceptibility (3–7),
nevertheless, identification of new potential genes and pathways
related to disease pathogenesis remains a matter of great interest.
According to the present available evidence, alterations in the
metabolism of arachidonic acid (AA) and other polyunsaturated
fatty acids are involved into the pathogenesis of hypertension and
other cardiovascular diseases (8–10). Incorporated into mem-
brane phospholipids, AA is hydrolyzed by a Ca2+-activated phos-
pholipase A2 upon endogenous stimuli and oxidized by
cytochrome P450 epoxygenases to form epoxyeicosatrienoic
acids (EETs), potent lipid mediators with a wide range of biologi-
cal events in the cardiovascular system (11, 12). Functional effects
of EETs are realized through activating receptor-mediated signal-
ing pathways and ion channels (12). A number of preclinical and
genetic epidemiologic studies demonstrated that CYP-derived
epoxyeicosatrienoic acids possess potent vasodilatory, angiogenic,
and anti-inflammatory properties in the heart, vasculature, and
kidney and that genetically determined alterations in the metabo-
lismof EETsmay play an important role in the pathophysiology of
many cardiovascular disorders, including hypertension and its
complications (13, 14).
Cytochrome P450 2J (CYP2J2) and 2C (CYP2C8, CYP2C9 and
CYP2C19) are the twomajor subfamilies of CYP enzymes respon-
sible for the biosynthesis of EETs in the cardiovascular system (15,
16). Interestingly, experimental studies demonstrated that
increased expression of endothelial CYP2 epoxygenases lowers
blood pressure and attenuates hypertension-induced renal injury
in mice (17). Taken into account that genetically determined
differences in the expression or activity of these enzymes could
explain interindividual risks in developing hypertension, exploita-
tion of single-nucleotide polymorphisms (SNP) in genes encoding
these enzymes is become an attractive option for examining
genetic etiology of essential hypertension. Pursuing this interest,
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several genetic association studies have been undertaken to inves-
tigate the relationship between SNPs in CYP epoxygenase genes
and hypertension susceptibility in different human populations.
However, no association studies of CYP2C and CYP2J gene sub-
families have been so far undertaken on the animal model of
human hypertension. The relationship of polymorphisms of
CYP2C and CYP2J gene subfamilies and essential hypertension
risk has been investigated in various races and ethnicities includ-
ing African-Americans (18, 19), Chinese (20, 21, 22), Korean (23),
and Arab (24, 25) populations. A few genetic association studies
investigated CYP2C and CYP2J2 gene subfamilies SNPs and
hypertension risk have been done in European populations (18,
26, 27). However, these studies have yielded controversial results
and show that the pathogenetic role of CYP2C and CYP2J2 gene
subfamilies should be clarified by independent studies in different
populations. Our previous study in Russians has found a strong
association between promoter polymorphism -76G>T (rs890293)
of the CYP2J2 gene and the risk of essential hypertension (26)
highlighting the importance of P-450 epoxygenase pathway of
arachidonic acid metabolism in the pathogenesis of hypertension
in our population. Therefore, the present study was designed to
investigate whether common SNPs of CYP2C subfamily genes
such as CYP2C8 (rs7909236 and rs1934953), CYP2C9
(rs9332242), and CYP2C19 (rs4244285) are associated with sus-
ceptibility to essential hypertension in Russian population.
Methods
Study Population
A total of 816 unrelated Russian individuals comprising 425
patients with essential hypertension EH and 391 normotensive
controls were selected from the study samples recruited in our
previous studies (26, 28, 29). The study protocol was approved by
Ethical Review Committee of Kursk State Medical University, and
written informed consent was obtained from each participant
before the study. Diagnosis of essential hypertension was estab-
lished by qualified cardiologists according to WHO criteria. All
hypertensive patients had no clinical signs, symptoms, and labora-
tory findings suggestive of secondary hypertension. As can be seen
from Table 1, patients with EH were matched to healthy controls
on sex and age (P > 0.05). A percentage of positive family history
of hypertension was significantly greater in hypertensive patients
versus normotensive controls. No differences were found between
the groups regarding to other baseline characteristics.
Genetic analysis
Genomic DNA was isolated from venous blood samples using
a standard phenol/chloroform procedure. Genes encoding
CYP2C subfamily epoxygenases of responsible for the meta-
bolism of arachidonic acid into vasoactive eicosanoids were
selected based on their involvement in the pathway using
KEGG PATHWAY (www.genome.jp/kegg/pathway.html),
Reactome Pathway (www.reactome.org), and PharmGKB
(www.pharmgkb.org) databases. Four common SNPs of the
CYP2C gene subfamily as CYP2C8 (rs7909236, rs1934953),
CYP2C9 (rs9332242), and CYP2C19 (rs4244285) were selected
for this study. Genotyping of SNPs was performed using the
MassARRAY 4 system (Agena Bioscience Inc, San Diego, CA,
USA) at the Core Facility “Medical Genomics” in the Research
Institute of Medical Genetics (Tomsk, Russia). We failed to
genotype eight controls and four cases EH patients because of
low quality of their DNA samples.
To evaluate genotype–phenotype correlations, we used the
genotype and mRNA expression data available for 270
HapMap subjects from four populations and SNPexp v1.2
online tool (http://app3.titan.uio.no/biotools/tool.php?app=
snpexp). The functionality of selected SNPs was also assessed
in silico by the SNP function prediction tool developed by Xu
and Taylor (30) and available online at the SNPinfo Web
Server (https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm).
Data Analysis
Allele frequencies were estimated by the gene counting method,
and the chi-square test was used to identify significant depar-
tures from Hardy–Weinberg equilibrium. The distributions of
the genotypes and their combinations between patients and
controls were evaluated by logistic regression analysis.
Categorical variables such gender and family history of hyper-
tension were also compared by using the chi-square test. These
statistics were calculated by using STATISTICA software for
Windows 10.0 (StatSoft Inc., Tulsa, OK, USA) and the
SNPassoc package for R. The association between genotypes
and EH risk was measured by multiple logistic regression ana-
lysis to calculate odds ratios (OR) with 95% confidence intervals
(CI) and adjusted for age and gender. Pairwise gene–gene inter-
actions were evaluated by log-likelihood ratio test (LRT) assum-
ing codominant, dominant, and recessive models and adjusted
for age and gender (31). Generalized linear model (GLM) was
used for the genotype–phenotype correlation analysis to evaluate
the differences in the relative mRNA expression levels among
carriers with different genotypes using data from 270 HapMap
subjects.
Results
No departure fromHardy–Weinberg equilibrium for investigated
SNPs was noted in both EH and control groups (P > 0.05). Allele
and genotype frequencies in the studied groups were compatible
with those reported in European populations. Table 2 shows
genotype and allele frequencies of CYP2C subfamily gene poly-
morphisms in both case and control groups. Variant allele and
genotypes of CYP2C8 rs7909236 were found to be significantly
associated with increased risk of essential hypertension (P ≤
0.001). As can be seen from Table 2, association between geno-
types CYP2C8 and EH risk remained statistically significant after
adjustment for age and sex (P = 0.005). Moreover, allele C (OR =
Table 1. Baseline characteristics of the study groups.
Baseline characteristics
Controls,
n = 391
EH patients,
n = 425 P-value
Age, mean ± standard deviation 58.9 ± 8.4 59.0 ± 8.3 0.84
Males, n (%) 228 (58.3) 261 (61.4) 0.37
Body mass index
(kg/m2), mean ± standard deviation
27.5 ± 7.7 28.2 ± 9.4 0.24
Positive family history
of hypertension, n (%)
183 (46.8) 251 (59.1) 0.001
Bolded is statistically significant P value.
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1.22 95%CI 0.99–1.50, P = 0.06) and genotype CС (OR = 1.66 95%
CI 1.03–2.69, P = 0.035, recessive genetic model) of CYP2C8
rs1934953 were also associated with increased hypertension risk,
but at a borderline statistical significance. However, odds ratio of
EH risk in the carriers of CYP2C8 CС remained significant after
adjustment for age and sex (OR = 1.68 95%CI 1.04–2.72, P =
0.031). In addition, SNP rs4244285 of CYP2C19 tended to be
associated with a decreased risk of EH: Adjusted odds ratio for
sex and age in the carriers of genotype AA was 0.29 (95%CI 0.08–
1.05, P = 0.04).
Then, we applied a log-likelihood ratio in order to assess join
effects of CYP2C subfamily gene polymorphisms on EH risk.
Table 3 shows data on the analysis for epistatic interactions
between CYP2C subfamily gene polymorphisms in essential
hypertension, as evaluated by SNPassoc package for R.
Although, no statistically significant epistatic interactions between
the genes were observed, the crude effect of rs1934953 on the EH
risk was noted (P = 0.033, recessive genetic model). Further
analysis for gene–gene interactions (Table 4) observed that five
genotype combinations were associated with increased risk of
hypertension. However, the only genotype combination CYP2C8
rs7909236 TT × CYP2C19 rs4244285 GG was significantly asso-
ciated with EH risk after adjustment for multiple testing (P =
0.004).
Genotype–phenotype correlation analysis for CYP2C sub-
family gene polymorphisms was preformed using the data on
both mRNA expression levels and genotypes for these genes
obtained from 270 HapMap individuals. The relative expres-
sion levels of CYP2C subfamily genes mRNA by different
genotypes are shown in Figure 1(A, B, C and D) . The levels
of CYP2C8 mRNA were significantly correlated with SNP
rs2228099 (P = 0.01, Figure 1A) at dominant genetic model,
as evaluated by GLM. No significant genotype–phenotype
correlations were found for other investigated SNPs. in silico
functional analysis performed by the SNP function prediction
tool observed a regulatory potential for SNP rs1934953 of the
Table 2. Genotype and allele frequencies of CYP2C subfamily gene polymorphisms in hypertensive patients and controls.
Gene, polymorphism Genotype, allele
Controls,
n (%)1
EH patients,
n (%)1
P-value
OR (95% CI)2
P-value
adjOR (95% CI)
3
CYP2C8, G > T (rs7909236) GG 262 (67.0) 242 (56.9) 0.001 0.005
GT 118 (30.2) 151 (35.5) 1.27 (0.95–1.71) 1.38 (0.99–1.93)
TT 11 (2.8) 32 (7.5) 2.81 (1.40–5.66) 2.99 (1.39–6.44)
T 0.179 0.253 0.0003
1.55 (1.22–1.97)
-
CYP2C8, T > C (rs1934953) TT 181 (46.3) 178 (41.9) 0.084 0.083
TC 181 (46.3) 197 (46.4) 1.11 (0.83–1.48) 1.09 (0.82–1.46)
CC 29 (7.4) 50 (11.8) 1.75 (1.06–2.90) 1.76 (1.06–2.90)
C 0.306 0.349 0.061.22 (0.99–1.50) -
CYP2C9, C > G (rs9332242) CC 305 (79.6) 337 (80.0) 0.558 0.568
CG 71 (18.5) 80 (19.0) 1.02 (0.71–1.45) 1.03 (0.72–1.47)
GG 7 (1.8) 4 (1.0) 0.52 (0.15–1.78) 0.52 (0.15–1.81)
G 0.111 0.105 0.677
0.94 (0.68–1.28)
-
CYP2C19, G > A (rs4244285) GG 305 (78.0) 341 (80.2) 0.119 0.117
GA 74 (18.9) 80 (18.8) 0.99 (0.70–1.41) 0.95 (0.65–1.39)
AA 11 (3.1) 4 (0.9) 0.35 (0.12–1.06) 0.29 (0.08–1.05)
A 0.123 0.104 0.21
0.82 (0.61–1.12)
-
1 Absolute number and percentage of individuals with particular genotype.
2 Odds ratio with 95% confidence intervals (codominant genetic model).
3 Odds ratio with 95% confidence intervals adjusted for age and gender with two degrees of freedom.
Bolded is statistically significant P value.
Table 3. Epistatic interactions between CYP2C subfamily gene polymorphisms in essential hypertension. (Gene–gene interactions are evaluated by SNPassoc package
for R [González JR et al, 2007]).
SNPs
Genetic
models
CYP2C8
(rs7909236)
CYP2C8
(rs1934953)
CYP2C9
(rs9332242)
CYP2C19
(rs4244285)
CYP2C8
(rs7909236)
Сodominant – – – –
Dominant – – – –
Recessive – – – –
Overdominant – – – –
CYP2C8
(rs1934953)
Сodominant – 0.086 0.052 –
Dominant – 0.236 0.663 –
Recessive – 0.033 – –
Overdominant – 0.927 0.381 –
CYP2C9
(rs9332242)
Сodominant – 0.745 0.572 –
Dominant – 0.970 0.920 –
Recessive – 0.488 0.295 –
Overdominant – 0.917 0.835 –
CYP2C19
(rs4244285)
Сodominant – – – –
Dominant – – – –
Recessive – – – –
Overdominant – – – –
The upper part of the matrix contains the P values for epistatic interactions evaluated by log-likelihood ratio (LRT) test. The diagonal contains the P values from LRT
for the crude effect of each SNP. The lower triangle contains the P values from LRT comparing the two-SNP additive likelihood to the best of the single-SNP models.
Bolded is statistically significant P value for SNP–SNP interactions. P values are adjusted for age and gender.
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CYP2C8 gene (Figure 1E it is indicated by right red box). A
SNP rs9332242 is located at binding sites for mRNA.
Furthermore, SNP rs7909236 is located at binding site for a
number of transcription factors suggesting a functional sig-
nificance of this polymorphism of CYP2C8.
Discussion
In the present study, we investigated whether common poly-
morphisms of CYP2C8, CYP2C9, and CYP2C19, genes
involved into the epoxygenase pathway arachidonic acids
metabolism, are associated with susceptibility to essential
hypertension in Russian population. We found that SNPs
rs7909236 and rs1934953 of the CYP2C8 gene were signifi-
cantly associated with increased risk of essential hypertension,
whereas SNP rs4244285 of CYP2C19 tended to be associated
with decreased risk of the disease. Analysis for gene–gene
interactions revealed that combination of genotypes CYP2C8
rs7909236 TT and CYP2C19 rs4244285 GG was significantly
associated with increased risk of essential hypertension.
Genotype–phenotype correlation analysis showed that the
levels of CYP2C8 mRNA were significantly correlated with
SNP rs7909236. Functional prediction analysis performed in
silico revealed the functionality of majority of investigated
SNPs: a regulatory potential observed for SNP rs1934953 of
CYP2C8, SNP rs9332242 of CYP2C8 is located at binding sites
for mRNA, and SNP rs7909236 of CYP2C8 is located at
binding site for multiple of transcription factors.
To our knowledge, the present study was the first to show
that the investigated polymorphisms such as rs7909236 and
rs1934953 of CYP2C8 and also rs4244285 of CYP2C19 could
be novel genetic markers of susceptibility to essential hyper-
tension. We also found for the first time that synergistic
interactions between polymorphic genes of CYP2C subfamily,
at least between CYP2C8 rs7909236 and CYP2C19 rs4244285
loci, contribute to the increased disease risk. However, the key
finding was an increased risk for EH in carriers of the variant
T alleles of rs7909236. CYP2C8 is a cytochrome P450 enzyme
possessing epoxygenase activity and catalyzing an NADPH-
and oxygen-dependent conversion of arachidonic acid to a
cis-epoxyeicosatrienoic acid. The enzyme plays a major role in
the metabolism of therapeutically important drugs exhibiting
large interindividual differences in their pharmacokinetics
(32). In fact, little is known about how the expression of the
CYP2C8 gene is regulated. It is known that rs7909236
(-271C>A, CYP2C8*1B) is a promoter SNP located at -271
from the translational start of the CYP2C8 gene, and the
variant allele has been suggested to result in the creation of
a C/EBPalpha transcription factor consensus sequence and
associated with increased transcription factor binding and
promoter activity (32, 33). However, this is contrary to our
finding obtained on the HapMap data. We found that the
levels of CYP2C8 mRNA were decreased in the carriers of
genotype GT suggesting a downregulation effect of this var-
iant on the gene expression. Indeed, polymorphism rs7909236
of CYP2C8 could be the target for a number of transcription
factors, as we identified in silico by the function prediction
tool. This means that the expression of CYP2C8 is controlled
by diverse regulatory mechanisms such as inducible activation
by transcription factors, each of which bind to specific reg-
ulatory elements in this 5’-upstream region of the gene. We
did not find effects of other SNPs investigated in this study on
the expression levels of corresponding genes. Moreover, no
any functional studies were found in the literature regarding
to functional significance for that SNPs. This makes further
interpretation of association of these SNPs with hypertension
phenotype difficult.
Given that CYP2C-derived EETs are potent vasodilators,
persons with diminished capacity to synthesize EETs due to
the downregulation of CYP2C8 expression (i.e., carriers of the
-271T allele of rs7909236) might be more susceptible to
essential hypertension. Based on the reviewed literature (9,
10, 11, 14), we proposed the mechanisms by which plausible
deficiency of CYP2C-derived EETs in carriers of the -271T
allele of CYP2C8 might cause hypertension include: a)
decreased vasorelaxation and increased peripheral vascular
resistance due to diminished ion channel-dependent activa-
tion and insufficiency to stimulate the formation and release
of natural vasodilators (action as an endothelial derived
hyperpolarizing factor), b) increased cardiac contractility
and heart rate, c) increased cortical renin release and
decreased sodium excretion in kidneys due activating epithe-
lial sodium channel, and d) promoted both apoptotic and
oxidative vascular injury. Certainly, it is crucial that, before
drawing definitive conclusions about the mechanisms pro-
posed above, experimental and clinical studies utilizing cut-
ting edge molecular and biochemical technologies are
required to substantiate genotype–phenotype relationships in
the epoxygenase pathway of AA metabolism underlying
hypertension pathogenesis.
The present study has some limitations. A majority of the
associations of SNPs with hypertension risk were not strong,
Table 4. Overall associations between genotype combinations of CYP2C subfamily gene SNPs and essential hypertension risk.
Genotype combination Controls, n (%) EH patients, n (%) P-value OR (95% CI)1
1 CYP2C8 rs7909236 TT × CYP2C8 rs1934953 CC 10 (2.9) 22 (7.2) 0.01
2.57 (1.20–5.52)
2 CYP2C8 rs7909236 GT × CYP2C9 rs9332242 CG 13 (3.9) 23 (7.6) 0.04
2.04 (1.01–4.10)
3 CYP2C8 rs7909236 TT × CYP2C9 rs9332242 GG 10 (3.0) 20 (6.6) 0.03
2.30 (1.06–5.00)
4 CYP2C8 rs7909236 TT × CYP2C19 rs4244285 GG 8 (2.5) 21 (8.0) 0.004
3.34 (1.48–7.51)
5 CYP2C8 rs1934953 CC × CYP2C19 rs4244285 GG 27 (7.5) 42 (12.8) 0.02
1.81 (1.09–3.01)
1 Сrude odds ratio with 95% confidence intervals;
Bolded is statistically significant genotype combination after adjustment for multiple testing.
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thereby showing small-to-modest effects of these genes on disease
phenotype. Because a limited number of SNPs were selected for
this study, our findings do not allow any definitive conclusion yet
to be made on the comprehensive contribution of the genes to
hypertension susceptibility. This means that the results of our
study require further investigation in other population-based stu-
dies to address issues discussed above, but these studies will need
to be substantially larger than the present investigation. It is
important to note that since essential hypertension is a multi-
factorial disease determined by a complex interplay between
genetic and environmental factors, further genetic studies should
take into account disease-associated environmental risk factors to
better understand the molecular mechanism of the disease
development.
Nevertheless, a preliminary conclusion has to be made that
polymorphic genes of CYP2C subfamily are important deter-
minants of genetic susceptibility to essential hypertension. An
association between polymorphisms of these genes and hyper-
tension demonstrates the importance of the epoxygenase
pathway in the metabolism of arachidonic acids for the dis-
ease pathogenesis. Understanding the relationships between
altered CYP2C9 gene expression and hypertension pathophy-
siology should suggest specific targeted interventions that will
expand the therapeutic options for hypertensive individuals in
future. For instance, the modulation of EET pathway through
stimulation of residual enzyme activity represents a promising
pharmacological target that may improve the clinical manage-
ment of hypertensive patients and healthy individuals at high
cardiovascular risk.
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Figure 1. Functional analysis of CYP2C subfamily gene polymorphisms. A, B, C, and D. The relative expression levels of CYP2C subfamily genes mRNA by different
genotypes in 270 HapMap subjects from four populations analyzed by the HumanWG-6 Expression BeadChip and evaluated by SNPexp v1.2 online tool (Norwegian
PSC Research Center, http://app3.titan.uio.no/biotools/tool.php?app=snpexp). Red arrow shows significant effects of SNP on gene expression levels. The effects of
SNPs on mRNA levels of corresponding genes are evaluated by generalized linear models (GLM). E. SNP function prediction results evaluated by FuncPred online tool
(National Institute of Environmental Health Sciences, https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm). NA, not available; TFBS, Transcription Factor Binding Sites;
ESE, Exonic Splicing Enhancer; ESS, Exonic Splicing Silencer; Polyphen, predicted damaging nsSNPs; RegPotential, Regulatory Potential Score; Y, Yes; N, No.
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